Open-label Phase-4 Study to Examine the Change of Vision-related Quality of Life in Subjects With Diabetic Macular Edema (DME) During Treatment With Intravitreal Injections of 2 mg Aflibercept According to EU Label for the First Year of Treatment
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 23 May 2017
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms AQUA
- Sponsors Bayer
- 13 Jul 2016 Status changed from recruiting to active, no longer recruiting.
- 08 Jun 2016 Planned End Date changed from 1 May 2017 to 1 Aug 2017.
- 08 Jun 2016 Planned primary completion date changed from 1 May 2017 to 1 Aug 2017.